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ABSTRACT
Healthcare-associated infections (HAIs) have been a hot topic for several decades. An understanding of
HAIs should be based on an understanding of the organisms that cause infection and determine
prevention. Although some improvements in control in hospitals have been recorded, the community
setting is now implicated, and the role of microbiology in diagnosis, detection of carriers and strain
typing of organisms is evident. As healthcare systems vary widely, prevention strategies must be
designed accordingly. Hand hygiene, however, remains applicable in all settings, and the WHO is
strongly promoting alcohol-based hand rubs to interrupt transmission. Some countries are only
beginning to develop standards, whereas compliance is obligatory in others. Economics and cost factors
are common to all countries, and litigation is increasingly a factor in some.
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Healthcare-associated Infections (HAIs) have
been a hot topic for several decades, and consti-
tute an issue of increasing importance now that
medical care involving the risk of infectious
complications (surgery, intensive care, grafts,
etc.) is being delivered to populations with
increasing susceptibility to infection (e.g. those
who are of advanced age and those who are
immunodeﬁcient). For this reason, the healthcare
community is spending increasing time and
resources to address this issue, leading to pro-
gress in various aspects of HAIs.
Like community-acquired infections (CAIs),
HAIs offer a wide range of models with distinct
consequences for prevention, diagnosis and
treatment. Indeed, the basic features of the micro-
organisms involved and the risk factors deter-
mine the type of HAI. Recent developments in
microbiology have provided improved under-
standing and better tools with which to document
situations and anticipate evolutions.
Furthermore, HAIs occur within healthcare
systems which are very diverse in medical scope,
resources and style of management, reﬂecting
socio-economic and cultural differences. Most
countries address the issue of HAIs in their own
context, and therefore with different organiza-
tions and priorities.
An International HAI Forum, held early June
2007 in Les Pensie`res, near Annecy, France,
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provided the opportunity to exchange data and
perspectives on HAIs from a multidisciplinary
and global perspective. This report covers the key
themes discussed during the Forum, namely, the
factors driving HAI risk, multidrug resistance and
HAIs, intercontinental HAI strategies, HAI and
genetics, and societal aspects of HAIs.
FACTORS DRIVING HAI RISK
HAIs arise from the interaction of several factors:
pathogenicity of microorganisms, general and
local patient immunity, iatrogenic procedures,
cross-contamination and antibiotic pressure.
HAIs and pathogenicity of microorganisms
The microorganisms involved in HAIs can be
schematically classiﬁed into three groups accord-
ing to their ecological features and pathogenicity.
Commensal bacteria, which constitute normal
patient ﬂora, are the most frequent agents of
HAIs. The main reasons for this are: (i) the huge
number of these bacteria (1013, of which 109 are on
the skin, 1010 in the nasopharynx and 1013 in
faeces, exceeding the number of eukaryotic cells
in the human body); (ii) their permanent pres-
ence, ensuring that they are always ‘on hand’,
particularly in the case of invasive procedures;
and (iii) the fact that, although commensal,
several species have marked potential pathoge-
nicity, allowing them to easily create infections
when introduced into sterile body sites. Staphylo-
coccus aureus, Escherichia coli and Enterococcus spp.
are the three main commensal species involved
in HAIs, accounting, respectively, for c. 15–20%,
20–25% and 0–5% of the cases. Altogether,
commensal species account for 70–80% of HAIs.
Saprophytic bacteria (e.g. Pseudomonas aerugin-
osa, Enterobacter spp., Serratia spp. and Acinetobac-
ter baumannii) present in the environment (e.g.
water, air and soil) can colonize patients, partic-
ularly those receiving antibiotic therapy, and can
cause infections in the case of invasive proce-
dures. Other saprophytic organisms (e.g. Legio-
nella and Aspergillus) can be disseminated among
patients via air or water systems. The incidence of
HAIs due to Legionella and Aspergillus depends on
the types of patient in the hospital and on efforts
to control water and air supply systems. Alto-
gether, saprophytic species account for c. 20–25%
of HAIs, and P. aeruginosa is the third most
frequently involved species in HAIs (c. 10%).
The most frequently involved saprophytic Entero-
bacteriaceae are Enterobacter spp. (c. 5% of HAIs).
A. baumannii is responsible globally for less than
2% of HAIs, but can be involved in epidemics,
mostly in intensive care units (ICUs). Finally,
highly pathogenic organisms that are major
agents of CAIs (e.g. Mycobacterium tuberculosis,
inﬂuenza virus, rotavirus, hepatitis B virus and
hepatitis C virus) are less common causes of HAIs
(less than 5%), but can cause severe infections or
epidemics in certain settings (e.g. among geriatric
and paediatric populations).These three groups of
organisms cause HAIs that differ widely in their
nature and epidemiology, and this affects the
preventive measures needed to control them.
Risk factors
Invasive procedures are major risk factors for
HAIs. On the one hand, these procedures are used
with increasing frequency (e.g. surgery and intra-
vascular devices), but on the other hand, the risk
of infection is progressively controlled by revising
and reinforcing preventive measures. It should
be noted that nowadays iatrogenic risks and
‘nosocomial’ infections can also occur outside
the hospital setting (e.g. in ambulatory care),
justifying the use of the term HAI in place of
‘nosocomial’.
Many hospitalized patients are immunocom-
promised and therefore at high risk of infection,
even by microorganisms with low pathogenicity.
For these reasons, uncommon types of HAI should
now be recognized by laboratories, physicians and
epidemiologists (e.g. bone and joint infections due
to Propionibacterium acnes, urinary tract infections
(UTIs) due to Corynebacterium urealyticum, and
surgical wound infections (SWIs) due to fast-
growing mycobacteria such as M. chelonae).
Cross-contamination
Exchange of commensal ﬂora is natural among
humans, and cross-contamination is the key route
of transmission for many pathogenic microorgan-
isms. In the hospital setting, cross-contamination
is ampliﬁed by the density of patients and the
number of direct contacts between healthcare
workers (HCWs) and patients. Cross-contamina-
tion can be reduced by standard precautions,
especially hand hygiene. Signiﬁcant improve-
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ments have been achieved in recent years through
the introduction of alcohol-based hand rub (AHR)
solutions, which greatly simplify disinfection.
Owing to the cumulative risk of invasive
procedures, immunodeﬁciency and cross-contam-
ination, HAI risk increases with extended length
of hospital stay.
Antibiotic pressure and antibiotic resistance
The majority of patients are given antibiotics
before and ⁄ or during their hospital stay, leading
to strong antibiotic pressure that is much higher
in hospitals than in the community. Such pressure
favours the development of antimicrobial resis-
tance, which is ampliﬁed by cross-contamination
of patients with resistant strains. In turn, antimi-
crobial resistance makes the treatment of HAIs
more difﬁcult and leads to increasing use of
newer drugs, active against multidrug-resistant
(MDR) organisms. The issues of resistance and
HAIs are clearly linked, each contributing to the
propagation and severity of the other, and should
therefore be addressed simultaneously.
HAI PREVALENCE AND TYPES
Many studies have been performed concerning
the surveillance and epidemiology of HAIs. Their
prevalence appears to be quite similar in many
developed countries, e.g. averaging 8% of hospi-
talized patients in Europe, with national values
ranging from 6% to 12%. In the USA, an esti-
mated total number of 2 000 000 HAIs occur
every year. However, such estimations may vary
according to the deﬁnitions, statistical computa-
tion models, and methods of data disclosure.
In all developed countries, the most frequent
types of HAI are:
1 UTIs (30–40% of HAIs), which are mainly due
to indwelling catheters, but which may also
occur in the absence of invasive procedures in
the elderly and in pregnant women. Despite
their moderate rates of morbidity per se, UTIs
affect the overall condition of patients and
extend the length of hospital stay.
2 Lower respiratory tract infections (LRTIs; 10–
20% of HAIs) that are caused by mechanical
ventilation during surgery or in ICUs (ventila-
tor-assisted pneumonia (VAP)), but which also
occur in the same way in which community-
acquired LRTIs occur in geriatric and paediat-
ric settings and in long-term-care facilities (e.g.
infections due to inﬂuenza virus, respiratory
syncytial virus or Streptococcus pneumoniae).
LRTIs have a high mortality rate.
3 SWIs, which are a major issue in terms of
number of cases (10–20% of HAIs in acute-care
facilities, and occurring after 1–5% of surgical
procedures, depending on the type of proce-
dure and patient, as demonstrated by US
National Nosocomial Infection Surveillance
data) and severity. SWIs are a common cause
of legal suits.
4 Skin and soft tissue infections (SSTIs), which
account for c. 10% of HAIs and are particularly
common in the elderly population in long-
term-care facilities.
5 Bloodstream infections (BSIs) that are compli-
cations of intravascular devices or of other
HAIs, mainly UTIs, LRTIs and SWIs. Less
frequent than other HAIs (c. 5%), BSIs often
have a fatal outcome.
MULTIDRUG RESISTANCE AND
HAIS
Methicillin-resistant S. aureus (MRSA) in HAIs:
a worldwide challenge
MRSA is an organism of major importance in
HAIs. The prevalence of MRSA among S. aureus
isolated from hospitalized patients differs widely
from country to country, depending on national
policies, ranging from high (more than 20%) in
the USA, Australia, Japan, Israel, France, Italy,
Spain and the UK, to low (less than 5%) in The
Netherlands, Sweden, Denmark and Switzerland.
However, some countries that are free of endemic
MRSA have developed low endemicity in recent
decades.
S. aureus is both a human commensal bacte-
rium present on skin and in the nares of c. 30% of
healthy people (natural carriers) and one of the
top pathogens in a large range of human CAIs
and HAIs, owing to the large number of enzymes
and toxins that this species can produce. This
species has also developed resistance to many
anti-Gram-positive antibiotics, mainly b-lactams,
but also macrolides, rifampin and fusidic acid [1].
As MRSA combines virulence, survival ﬁtness
and resistance to antibiotics, it has great epidemic
potential to cross-contaminate easily (from
human skin and mucous surfaces), abetted by
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the widespread use of b-lactams. MRSA HAIs are
difﬁcult and expensive to treat, and lead to high
morbidity and mortality rates. As an example, the
number of yearly death certiﬁcates with MRSA as
the underlying cause increased in the UK from
fewer than 50 in 1993 to more than 300 in 2004.
Controlling endemic MRSA relies on four main
actions [2]: (i) identiﬁcation and isolation of
carriers; (ii) elimination of carriage; (iii) elimina-
tion of transmission via hand hygiene; and (iv)
reduction in antibiotic use. The solution is to
reduce cross-transmission by multimodal inter-
ventions [3].
Several international surveillance systems have
been set up to monitor the progress of MRSA
epidemics and the impact of control programmes,
e.g. the European Antimicrobial Resistance Sur-
vey System in Europe (http://www.rivm.nl).
Interestingly, some experiences suggest that
MRSA epidemics can be curbed in hospitals if
active and long-lasting control programmes are
implemented. Following the implementation of
speciﬁc programmes for limiting cross-transmis-
sion, ﬁrst at the regional level and subsequently at
the national level, MRSA infection rates decreased
by almost 50% between 1993 and 2006 in Paris
hospitals (Assistance publique-hoˆpitaux de Paris,
http://www.onerba.org) and by 20% from 2001
in more than 50 French hospitals across the
country (http://www.rivm.nl).
A review of recent publications shows that
several types of action can help control epidemic
situations: decontamination of patient skin
(chlorhexidin), environmental disinfection
(bleach), hand hygiene (AHR), isolation of MRSA
carriers, and antibiotic restriction (e.g. of ﬂuor-
oquinolones). Control is particularly effective
when several actions are combined in a multi-
modal ‘search and destroy’ package strategy [2].
However, despite some success stories, controlled
studies have provided limited evidence of control
in endemic situations [4]. Rapid molecular tests
for MRSA detection, if linked with multimodal
intervention, could represent progress in this
area.
Community acquired MRSA (CA-MRSA): an
emerging health problem that could also invade
hospitals
CA-MRSA is a new challenge that is clearly
distinct from hospital-acquired MRSA. This par-
ticular MRSA group, which is easily transmitted
from person to person in small communities,
carries a virulence factor, Panton–Valentine leuk-
ocidin (PVL). PVL, a toxin encoded on a phage
(USLT), has the ability to necrotize skin and soft
tissues as well as lung tissue within several
weeks. CA-MRSA stemmed from the insertion
of an SSCmec cassette encoding b-lactam resis-
tance into PVL-producing, methicillin-susceptible
S. aureus.
CA-MRSA strains are totally different from the
hospital-acquired MRSA strains that have been
spreading in hospitals for 40 years. Today, ﬁve
main features characterize CA-MRSA:
1 Diffusion of different clones, as characterized
by multilocus sequence typing, in different
parts of the world: USA300 in North America;
ST300, ST93 and ST377 in Australia; ST5, ST22
and ST80 in Europe, and ST524 in Asia.
Countries with a high level of international
exchange show the highest clonal diversity (for
example, many cases of the USA300 clone have
been detected in Denmark, where the ST80
clone has been prominent since 1995).
2 Usual susceptibility of CA-MRSA to many
antibiotics other than b-lactams. This situation,
however, is evolving, and the acquisition of
resistance to other antibiotics (e.g. kanamycin,
tetracyclines, erythromycin and fusidic acid)
has been observed.
3 Variable prevalence from country to country;
their is a high prevalence in the USA and a low
prevalence in Europe, except in Greece.
4 Numerous outbreaks among social minorities
(Native Americans in the USA, Aborigines in
Australia) as well as in particular populations
(intravenous drug users, athletic team mem-
bers, military recruits, incarcerated popula-
tions and kindergarten children).
5 Potential for hospital invasion, where CA-
MRSA prevalence is high, leading to HAIs.
The rate of carriage of CA-MRSA in the general
population is usually low (2–3%), but a high rate
(31%) has been found in a group of Eskimos.
Indeed, carriers are mainly infected patients,
owing to the high pathogenicity of CA-MRSA.
Most CA-MRSA infections are SSTIs, which are
mainly treated by surgery, with antibiotics having
only a minor effect on outcome. The presence of
PVL in MRSA increases the risk of death in severe
infections, particularly in cases of necrotizing
pneumonia (75% mortality rate).
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CA-MRSA is now a major health issue in the
community setting, particularly in low-hygiene
social groups. The spread of these strains should
be controlled in the community by increasing the
level of general hygiene (e.g. improving hand
hygiene and refraining from sharing personal
items such as towels). Decolonization of carriers
can prevent transmission within closed commu-
nities (e.g. within families).
Relevance of clones in HAI epidemics
In many situations, the identiﬁcation of bacteria
at species level is not sufﬁcient for epidemiolog-
ical investigation. Sub-speciﬁc identiﬁcation
using a genomic approach (molecular typing)
now has many very useful applications in the
context of HAIs, such as providing evidence of
clonal outbreaks and allowing investigation of
the characteristics of these outbreaks (e.g. rates
and modes of transmission, and role of the
environment and HCWs), identifying new
emerging clones (e.g. clones carrying new resis-
tance traits), assessing clonal tenacity, and
enabling traceability of patient ⁄ clone evolution
over time.
For instance, extended-spectrum b-lactamase
(ESBL)-producing Enterobacteriaceae in faecal car-
riers were studied by pulsed-ﬁeld gel electropho-
resis in Madrid (Spain) in 2004 and 2005,
revealing that: (i) 49% of index cases had the
same ESBL-producing E. coli strain in faeces and
at the infection site; (ii) 51% had the same ESBL
gene in another E. coli strain; and (iii) 55% of
cohabitants carried the same ESBL-producing
E. coli strain as the index case, whereas 45%
carried the ESBL gene in another E. coli strain.
Many procedures (c. 15%) can be applied to
investigate clonality in bacteria causing HAIs (e.g.
pulsed-ﬁeld gel electrophoresis, multilocus
sequence typing, random ampliﬁcation of
polymorphic DNA, repetitive extragenic palin-
dromic-PCR, and variable-number tandem repeat
polymorphism). The most sophisticated methods
rely on genomic analysis of the whole genome by
hybridization on microarrays (oligoarray typing).
Several methods can also be applied to investigate
antibiotic resistance-mediating plasmids, and
have demonstrated their value in improving
knowledge of plasmid evolution and ecology as
well as integron typing (e.g. of IncH12 plasmids
carrying blaCTX-M-9).
Relevance of integrons in multidrug resistance
Integrons have a major role in the development of
multiple antibiotic resistance in Gram-negative
bacteria. Integrons are small DNA structures
deﬁned by an integrase-encoding gene (specifying
a tyrosine recombinase), a recombination site (attl)
adjacent to the integrase gene, and an array of
resistance gene cassettes. A unique property of
integrons is the high tolerance of their recombina-
tion system,which isdue to the fact that the cassette
recombination sites are only distantly related.
Five classes of mobile integrons (MIs), encoding
integrases with 45–58% amino acid identity, carry
at most eight resistance cassettes: the Tn402 family
(including themost ubiquitousmember, Tn21), the
Tn7 family, classes 3 and 4 (on self-transmissible
plasmids), and class 5 (SXT elements).
Superintegrons (SIs) have been found in the
chromosomes of some species (Vibrio cholerae).
They are characterized by a larger size, unknown
functions of most cassettes, and homology of the
SI attC sites when compared to the MI attC sites,
enabling MIs to receive cassettes from SIs. MIs
can evolve from chromosomal SIs, exploiting
three properties: the presence of a protoresistance
gene such as chloramphenicol acetylase (cat) in
Vibrio cholerae or b-lactamase (bla) in environ-
mental V. Cholera, the ability to recombine dis-
tantly related sequences (recombination sites are
recognized and recombined in single-strand form
into the double-strand platform), and concerted
expression of the integrase.
Conceptually, integrons offer an opportunity to
develop an inhibitor of gene cassette capture that
would limit the accumulation of resistance traits.
However, the signal(s) triggering integrase
expression is (are) still unknown.
ESBL-producing Enterobacteriaceae and the
spread of new enzymes: the double UK
epidemic
Resistance to third-generation cephalosporins via
ESBLs has been spreading in the UK since the
mid-1980s. An increasing number of classes of
enzymes (e.g. TEM, SHV and CTX-M) and an
increasing number of enzymes within each class,
especially TEM and CTX-M, as well as the
diversity of genomic structures carrying ESBL
genes (e.g. plasmids and integrons), make the
epidemiology of ESBLs very complex. The recent
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emergence of CTX-M-15-producing E. coli is now
a global concern.
The current ESBL epidemic in the UK has
been detected through systematic bacteraemia
surveillance. Resistance to third-generation ceph-
alosporins in E. coli from bacteraemias increased
from less than 2% to 9% over a 5-year period
(2001–2005), and most of the resistant strains
(80%) were also resistant to ciproﬂoxacin. These
data place the UK, along with Spain, Italy and
Greece, in the group of countries where the rate of
third-generation cephalosporin-resistant E. coli in
bacteraemias is 5–10% (http://www.rivm.nl),
whereas rates in Germany, Sweden and France
are 1–5%. The prominent ESBL class involved in
the UK E. coli epidemic is CTX-M (c. 75% in 2004
in south-east England); 90% belong to group 1
and 8% to group 9. CTX-M-15 represents a large
proportion of CTX-M group 1 cases. A single
clone producing CTX-M-15, named strain A, rep-
resents c. 25% of cases. In contrast, CTX-M-9-like
enzymes were mostly observed in distinct strains.
CTX-M-15 strain A carries the large pEK499 plas-
mid (117 kb) and usually also produces two other
b-lactamases, TEM-1 and OXA-1, as well as
having several genes for resistance to non-b-
lactam antibiotics (aminoglycosides, quinolones,
chloramphenicol, sulphonamides and trimetho-
prim). Some A strains are also resistant to carba-
penems, owing to the loss of major outer
membrane proteins. Strain A belongs to phyloge-
netic group B2 and exhibits a speciﬁc virulence
pattern, different from other clones. The plasmid
encodes two ‘addiction systems’ that force host
cells to keep the plasmid, even after the removal of
antibiotic selective pressure.
Rapidgenetic identiﬁcationof strain Areliesona
400-bp sequence of the CTX-M-15 bla gene and IS26
inserted between the bla gene and its usual pro-
moter, a genetic characteristic that leads to lower
levels of resistance to cephalosporins, as compared
to other CTX-M-15-producing strains. Several
questions regarding the ‘success’ of strain A dis-
semination remain unanswered, and treatment is
not yet optimized, as there is a lack of novel agents
that are active against these multiresistant strains.
Vancomycin-resistant enterococci (VRE) in
Europe and the USA
In Europe, the major reservoir of VRE was
initially the healthy population in the community,
of which 2–10% were carriers. The source was
probably the VRE reservoir in animals, which was
attributed to the widespread use of avoparcin
(a glycopeptide similar to vancomycin) as a
growth promoter during the 1980s. This source
decreased (e.g. in poultry) following the banning
of this antibiotic in 1995. In Europe, the propor-
tion of VRE among enterococci isolated in hospi-
tals was generally low (<5%), in contrast to the
USA, where hospitalized patients form the main
reservoir [5]. The major type of VRE is Enterococ-
cus faecium carrying the vanA gene, the ﬁrst gene
described as conferring glycopeptide resistance.
Occasionally, Enterococcus faecium carrying the
vanB gene or Enterococcus faecalis carrying vanA
is involved.
It should be noted that the percentage of VRE in
blood isolates is currently evolving in Europe, as
shown by the EARSS data (http://www.rivm.nl/
earss/). Whereas the percentage of VRE remained
below 5% during 2002–2005 in many countries
(e.g. Sweden, Norway, Finland, France, The
Netherlands and Spain), this percentage
increased from less than 5% to 5–10% in Germany
and Belgium, and from 5–10% to 25–50% in
Ireland, Portugal and Greece. Italy and the UK
also have a high percentage of VRE (10–25% and
25–50%, respectively). Numerous hospital out-
breaks have been reported in Europe in recent
years. For example, outbreaks occurred in hospi-
tals in three regions in France in 2004–2006. Late
implementation of control measures and rapid
dissemination of VRE by cross-transmission, lead-
ing to intestinal colonization of contact patients,
made it difﬁcult to control these outbreaks. There
are probably two reasons for the late emergence
of VRE in Europe as compared to the USA: (i)
changes in antibiotic use, i.e. the increase in use of
vancomycin due to MRSA and otherwise antibi-
otic-resistant Clostridium difﬁcile; and (ii) the
emergence of new clones that are better adapted
to hospital settings. Among these clones, CC17
appears to be a ‘superclone’, being highly resis-
tant to ampicillin and ﬂuoroquinolones, and
harbouring virulence factors such as the surface
protein Esp encoded by a putative pathogenicity
island [6].
VRE control in hospitals is based on two
principles and follows from the fact that the
infection ⁄ colonization ratio is greatly unbalanced
(c. 1 : 10), and thus the ﬁrst case of VRE infection
(i.e. positive clinical sample) indicates many
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undetected cases of colonization. Consequently,
the ﬁrst case of VRE infection should trigger: (i)
immediate screening of all contact patients,
according to the ‘concentric circles’ principle;
and (ii) immediate isolation of carriers and control
of patient transfers.
C. difﬁcile: the Canadian experience
C. difﬁcile-associated disease (CD-AD) ranges in
severity from mild diarrhoea to serious life-
threatening pseudomembranous colitis that can
have a fatal outcome [7]. C. difﬁcile is an anaerobic
Gram-positive organism that exists as a vegetative
form (the replicative form) producing toxins A
and B, and may also exist as a spore form that
allows it to survive in the presence of oxygen. The
spore is non-replicative and is resistant to the
action of antibiotics, heat and chemical disinfec-
tants. Approximately 10% of healthy adults and
30% of hospitalized adults asymptomatically
carry C. difﬁcile in their gut. Recent data suggest
that the food chain may also be a reservoir of this
bacterium; for example, some ground pork and
beef samples contain spores that produce ten
CFUs per 100 g. Ingestion of spores from meat
may lead to transient presence of the organism in
the human gut.
CD-AD is an important problem in many
countries, e.g. Canada, where it is responsible
for 46% of the patients who are isolated as a
precaution (as compared with 38% of patients
isolated due to MRSA). The incidence of CD-AD
dramatically increased between 1991 and 2004 in
the Quebec area, where cases of CD-AD rose from
26 to 86 cases per 100 000 patient-days in 18–64-
year-old patients and from 85 to 1200 cases per
100 000 patient-days in the elderly. The primary
strain responsible for this increase was called
NAP1, which is the same as C. difﬁcile strain 027.
This more virulent strain overproduces both
toxins A and B [8]. It is found in both Europe
and the USA, and the latest Canadian outbreaks
spread from Quebec to Europe.
As the main reservoir of C. difﬁcile in the
hospital is the faeces of carriers, and as the spore
form is resistant to disinfectants, prevention of
cross-transmission and dissemination is based on
a multi-parameter approach including education
of staff, hand hygiene, sustained compliance with
environmental cleaning, and adequate reprocess-
ing of bedpans [9]. Hand washing using soap and
water is required, as AHRs cannot kill spores [10].
Disinfection of the hospital environment requires
a combination of efﬁcient physical cleaning and a
disinfectant that has some sporicidal activity.
Ensuring compliance of housekeeping staff with
the cleaning protocol is critical. Monitoring of
compliance with the cleaning protocol can be
checked using UV–visible water-soluble markers,
which help to pinpoint insufﬁciently cleaned
areas. Thermal treatment of bedpans at 60C is
insufﬁcient to kill C. difﬁcile spores. C. difﬁcile has
very unique pathogenic characteristics, and con-
trol of its spread within the healthcare environ-
ment requires recognition of the role of the spore
in infection transmission.
STRATEGIES FOR HAIS :
INTERCONTINENTAL EXPERIENCES
The search and destroy strategy against MRSA
in The Netherlands
The Netherlands has maintained a low prevalence
of MRSA (<1%) over the past 30 years. The search
and destroy policy was deﬁned and implemented
after several outbreaks in the early 1980s. These
outbreaks were stopped by immediate and strin-
gent control measures, i.e. strict isolation of
patients and search for carriers. A speciﬁc lesson
drawn from this period concerns screening of
patients coming from hospitals in countries where
MRSA is endemic [11].
The key elements of the Dutch strategy are: (i)
pre-emptive isolation and screening of patients
coming from foreign hospitals; and (ii) immediate
isolation of every new case of MRSA (infection or
colonization) in conjunction with screening of
contact patients and care-givers and decontami-
nation of carriers with mupirocin. If more cases
are observed, isolation becomes collective for the
entire ward and admissions are discontinued [12].
This strategy is supported by a national guide-
line (WIP, http://www.wip.nl), a national surveil-
lance programme organized by the Institute of
Public Health (RIVM), and by standardizedMRSA
detection procedures (national guidelines from the
Dutch Society of Medical Microbiologists ).
The same policy also targets several other
highly resistant microorganisms (HRMOs), e.g.
ESBL-positive Enterobacteriaceae and VRE. Speciﬁc
attention is given to high-risk departments with
patients coming from foreign hospitals, from
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Dutch hospitals with a known HRMO problem, or
from HRMO patient contacts. Isolation
procedures are determined according to the
organisms and the types of resistance traits. The
WIP guideline also provides indications on con-
tact investigation and outbreak control. Indepen-
dently of the HRMOs targeted, the key factors for
success are: (i) early reaction upon ﬁrst appear-
ance’ (ii) adequate resources, both ﬁnancial
and personnel, for detection and isolation;
(iii) isolation according to national guidelines;
(iv) endorsement of guidelines by an inspectorate;
and (v) prudent use of antibiotics according to a
national antibiotic policy (http://www.swab.nl).
Developing a culture of safety in the USA
As in most western countries, healthcare in the
USA traditionally focuses on the individual rather
than on the population as a whole. Public health
is decentralized and underfunded, and hospitals
are mainly private, except for a few public
hospitals and Veteran Administrations. The three
major sources of funding are private insurers,
government services (Medicare, Medicaid) and
individuals. Traditionally, healthcare epidemiol-
ogy and infection control have focused more on
surveillance and less on intervention and imple-
mentation. A strong movement started in 2001 to
‘close the quality gap’ in US hospitals, with the
aims of offering performance expectations, guid-
ing the patient–clinician relationship, aligning
payment ⁄ accountability with quality improve-
ment, and promoting evidence-based practice.
Today, several forces impact on infection con-
trol in the USA. The government-run Agency for
Healthcare Research and Quality sets priorities
for patient safety, provides grants to study safety
issues, and develops practice guidelines (hand
hygiene, barrier precaution, prudent antibiotic
use, and prevention of UTIs, central-vein catheter
(CVC)-related BSIs, SSTIs and VAP). ‘Centers of
excellence’ organized by the CDC to study HAIs
and MDR infections promote an epidemiological
approach to the control of HAIs and of outbreaks,
and propose, as targets, the reduction of CVC-
related and surgical adverse events, as well as
antimicrobial-resistant infections, by 50%, and
100% adherence to HCW vaccination guidelines.
The NNIS, now called the National Healthcare
Safety Network, which is a CDC-driven reporting
system, is successful because it is conﬁdential,
voluntary and methodologically sound, monitor-
ing rates and links to prevention efforts and
communicating data back to healthcare providers.
US healthcare providers have initiated the Leap-
frog Group, composed of more than 150 health-
care organizations that represent more than
34 000 000 consumers in all states and works
with experts to improve patient safety. Consum-
ers have developed the National Quality Forum
(http://www.qualityforum.org), a non-proﬁt
organization that endorses consensus-based
national standards and develops technical
advisory panels. The Joint Commission on
Accreditation of Healthcare Organizations is an
independent non-proﬁt organization that sets
standards and accredits healthcare facilities in-
cluded in the 2001 Patient Safety Standards. Large
campaigns dedicated to patient safety have been
organized (e.g. the ‘100 000 lives’ campaign
http://www.ihi.org), and the HAI issue is mov-
ing from the scientiﬁc community into the lay
press. Finally, public reporting has been set up in
several states in the USA (e.g. Texas and Florida),
and the Society for Healthcare Epidemiology of
America (SHEA) has developed guidelines
requiring the participation of experts and the
use of standard deﬁnitions and performance
indicators (e.g. BSIs in ICUs and percentage of
HCWs vaccinated against inﬂuenza).
All these forces act in synergy and contribute to
a culture of safety in the USA, relying on
executive leaders, professional teams and staff
to: (i) engage (make the problem real, admit that
harm is untenable); (ii) educate (present the
evidence, identify changes needed); (iii) execute
(reduce complexity, hold regular team meetings);
and (iv) evaluate (based on measurement and
feedback, recognition and visibility).
To summarize, public awareness has forced
healthcare epidemiology and infection control
programmes to shift their focus from surveillance
to intervention, to focus on outcome and process
improvements, to implement best practice, to
engage leadership in the prevention of adverse
events, to develop data to ‘prove value’, and to
present data openly.
Implementation of infection control in Poland
Under the previous political system in Poland,
notiﬁcation of nosocomial infections to health
authorities was mandatory in principle. However,
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the incidence of reported cases was very low, as:
(i) there was no professional training for nurses
and physicians, and no guidelines for infection
control were in existence; and (ii) hospitals were
ﬁnancially sanctioned for notiﬁed HAIs. Since the
change of regime in 1989, a whole range of
infection control measures has been adopted: the
creation of Polish Societies for Nosocomial Infec-
tions (1990) and for Hospital Hygiene (1999),
national guidelines for HAI control (2000), and a
national network for identiﬁcation of important
pathogens and new resistance mechanisms
(OPTY, 2000). The ratio of infection control nurses
(2 years of training, ﬁve educational centres) to
beds is now 1 : 250, but there is still a shortage of
infection control physicians, due to the low
prestige (and therefore income) of employment
in the ﬁeld of HAI control [13].
Data on MDR organisms in Polish hospitals
have been obtained through speciﬁc surveys and
participation in European programmes (EARSS,
European Surveillance of Antimicrobial Con-
sumption (ESAC), HELICS-IPSE and FP6-COBRA
projects). The rates of ESBL-producing strains in
2003–2004 (13 hospitals) were 2% among E. coli
and 40% among Klebsiella pneumoniae, 81% of the
strains producing CTX-M. VIM carbapemenase is
spreading in P. aeruginosa in several distinct
Polish regions, and the ﬁrst cases of Enterobacte-
riaceae producing this enzyme have been recently
identiﬁed. National MRSA rates rose from 13%
in 2000 (45% in ICUs) to 22% in 2005 (36% in
ICUs). The ﬁrst outbreak of VRE occurred
in 1997, and since then 15 outbreaks have been
identiﬁed, mostly involving Enterococcus faecium
[14]. Recent activities of interest in the context of
HAI include: (i) the release of recommendations
for antibiotic treatment and prevention of resis-
tance; and (ii) the new Act of Parliament that
includes a speciﬁc section devoted to HAI con-
trol, and should help to curb these rising MDR
organism ﬁgures.
Latin American efforts to promote HAI
awareness and share experience
HAI activities differ signiﬁcantly from one coun-
try to another in Latin America. Limited
resources, lack of awareness on the part of
national authorities, difﬁculty of access to current
knowledge (i.e. lack of publications in Spanish)
and the absence of networks are all limitations;
however, initiatives are developing. A Pan
American Society of Infection Control has
organized meetings since 1995 (e.g. ‘Nosocomial
infections, surveillance and management’ in San-
tiago de Chile in November 2006), and a Pan
American Health Organization is focusing on
protocols, evaluations and antimicrobial resis-
tance. A Masters degree in Infection Control is
now available in Valparaiso (Chile). Several valu-
able initiatives have been conducted over the past
few years, and the results are evident. For
example, at Roosevelt Hospital, Guatemala, the
rates of pneumonia, central-catheter infections
and UTIs decreased between 2004 and 2006. HAI
rates (UTI, BSI, SWI and VAP) also declined in
Peru between 2000 and 2005. The adherence to
hygiene procedures (hand washing and use of
gloves and masks) was evaluated in Peru in 2001.
Other studies have assessed the cost of HAIs in
Latin America: (i) the cost of extended hospital
stay due to SWI, UTI, BSI and VAP was assessed
in seven countries under the auspices of the Pan
American Health Organization; (ii) the cost of
extended hospital stay and antibiotic usage due to
SWI, UTI, BSI and LRTI was assessed in Chile;
and (iii) the cost of ineffective measures (e.g.
routine wound treatments or CVC cultures, and
extended duration of chemoprophylaxis for sur-
gery) was assessed in Paraguay and Chile. The
Chilean national programme launched by the
health authorities in the 1990s led to clear
improvements in compliance with prevention of
wound infection (elimination of shaving, anti-
biotic prophylaxis and postdischarge surveil-
lance), and in compliance with good practice to
prevent VAP in ICUs, and resulted in decreased
rates of VAP in ICUs.
These successful experiences can now be
shared among countries and regions. Today, the
challenges are the development of evidence-based
strategies, permanent supervision of practices,
indicators and surveillance. The 9th Congress of
the International Federation of Infection Control
that will be held in October 2008 in Santiago de
Chile will be an important trigger for actions to
meet these challenges.
Regional infection control network in Japan
Until recently, Japan had little experience in HAI
control, which is not favoured by some charac-
teristic features of the Japanese healthcare system:
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a fee-for-service ﬁnancial system, very few spe-
cialists in infection control (839 in 2006 compared
to 6056 in the USA), and a typically long duration
of hospital stay (24 days as compared to 4–9 days
in many western countries). As a consequence,
the level of antibiotic resistance (e.g. via MRSA) is
high in Japan.
Recently, health authorities proposed the estab-
lishment of nationwide and regional infection
control network systems. The Miyagi region
(north-east of the main island, Honshu) estab-
lished such a system in 1999, connecting 117
healthcare facilities: one teaching hospital
(Tohoku University), eight general hospitals (500
beds), medium-size and small hospitals (100–200
beds), and a public health centre. The key oper-
ation centre is located at the Infection Control
Unit of Tohoku University Hospital (seven phy-
sicians, two nurses, and three microbiology tech-
nologists) and a laboratory.
This network covers a wide range of actions:
1 Provision of information via joint workshops
every 3–4 months, guidelines for antibiotic use
(printed material, CD-ROM and DVD), and
training concerning HAI control in long-term-
care facilities and the ICU. From a pedagogical
point of view, a particularly interesting initia-
tive is the organization of ‘Kids’ infection
control seminars’ for 1–3-year-old children
and parents, co-sponsored by the Japanese
Board of Education. These seminars focus on
microbes and the importance of hand washing,
and deliver a ‘Master of hand-washing’ certif-
icate.
2 Incorporation of infection control interventions
in ward audits performed by the Tohoku
Infection Control Unit (using a standardized
check-list) in over 100 institutions from 2002
onwards.
3 Establishment of a back-up and support con-
sultation system (direct, phone, fax or Inter-
net) to monitor antibiotic resistance (e.g.
penicillin-resistant pneumococci) by the core
laboratory at Tohoku University and to pro-
vide crisis management training (an open-
college style programme for HCWs, including
HAI control, investigation, communication
and logistics).
Local results, such as a decline in MDR organ-
isms between 2003 and 2006, are already encour-
aging. This type of network organization is being
progressively extended to the whole of Japan, and
is connected to global management and surveil-
lance programmes.
The WHO campaign for patient safety, ‘Clean
care is safer care’
HAIs are a major concern all over the world,
including in developing countries, where the risk
is markedly higher than in developed countries.
No hospital, no country and no healthcare system
in the world can claim to have solved the
problem. Prevention strategies can reduce HAIs
in developed, transitional and developing coun-
tries, and many solutions are simple and not
resource-demanding. For these reasons, the WHO
launched the ‘1st Global Patient Safety Challenge’
on 13 October 2005, relying on the implementa-
tion of a multimodal programme in healthcare
settings. The centrepiece of the campaign is the
strategy to improve hand hygiene in healthcare
that focuses on ﬁve core components, as
explained in the ‘Guide to Implementation’,
which includes a pilot pack:
1 System change: AHRs at point of care, and
access to safe, continuous water supply, soap
and towels. AHRs represent the reference
standard of care, and the WHO promotes hand
antisepsis formulations and local production.
2 Training and education: an entire set of educa-
tional tools is made available for HCWs,
administrators and decision-makers, focusing
on ‘My 5moments for hand hygiene’ (i.e. before
patient contact, before aseptic tasks, after risk of
exposure to body ﬂuid, after patient contact,
and after contact with patient surroundings).
3 Measurement of compliance (observation and
feedback): a manual for observers provides a
standardized and simpliﬁed method (observa-
tion form, and measure of antibiotic consump-
tion) to assess outcome, i.e. hand hygiene
compliance rates.
4 Reminders in the workplace: posters with
translations and adaptations to local cultures.
5 Establishment of a climate of safety through
active participation at institutional and indi-
vidual levels, and self-conﬁrmed efﬁcacy at
both levels.
Early success has been seen in Switzerland,
with a 25% increase in hand hygiene compliance
within 4 months, leading to the prevention of an
estimated 17 000 infections and cost savings of
60 000 000 CHF in 2006.
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The WHO invites all member states to become
mobilized around the followings axes: pledge to
ﬁght, implementation, scaling up, sustainability,
and evaluation of impact. Data are needed to
assess the size and nature of the problem and to
create the basis for monitoring the effectiveness of
actions. Indeed, the ‘patient safety gap’ differs
widely from place to place, with certain countries
controlling the risks to patients much better than
others. This gap exists because tools are not being
used and actions are not being implemented
widely enough, but the WHO message is clear: ‘It
is now possible to improve hand hygiene in your
facility! It’s your duty to protect patients and
yourself! You can make a change’ (http://www.
who.int/gpsc/en/; patientsafety@who.int; http://
www.who.int/gpsc/country;_info/en/index.html).
SOCIETAL ASPECTS OF HAIS
Antibiotic use
As antibiotic consumption is, along with cross-
transmission of resistant organisms from human
to human, a major factor driving resistance, the
survey and analysis of antibiotic use in hospitals
is a key issue. Pharmaco-epidemiology provides
information enabling measurements for assess-
ment (providing league tables), for diagnosis
(locating problems), for improvements (determin-
ing progress), and for ecological purposes (estab-
lishing links with antibiotic resistance).
Antibiotic use can be measured at the patient
level (choice of antibiotic and dosage) or at the
population level (global quantities at the level of
country, region, hospital or ward). Contrasting
with the good quality of information on the
prescribing behaviour of general practitioners
from studies driven by pharmaceutical companies
and health insurance systems, the quality of data
on antibiotic use in hospitals is relatively poor.
Antibiotic use in hospitals can be expressed in
weight (grams) or units (vial packing), but is more
usefully expressed as deﬁned daily doses (DDD)
by dividing weight by standard daily dosage, as
recommended by the WHO. Actual days of treat-
ment or prescribed daily doses and number of
patients exposed to antimicrobials are more pre-
cise, but rely on a computerized delivery system at
the patient level. Antibiotic use should be reported
using a denominator such as the number of
patients, number of patient-days, bed-days, or
occupied bed-days, and admissions or discharge
ﬁgures. Several indicators can be used to express
antibiotic pressure in hospitals (the most common
being DDD ⁄patient-days and percentage of pa-
tients exposed to antibiotics), depending on the
surveillance goal. The ESAC programme (http://
www.esac.ua.ac.be) uses DDD and patient-days as
denominators, but is now (ESAC II) comparing:
(i) DDD with days of treatment per patient-day,
which can change when the actual dosage differs
from the standard dosage mentioned on the
Summary of Product Characteristics; and (ii)
patient-days with admission ﬁgures.
Each indicator brings its own speciﬁcity, and
several indicators can be complementary, yielding
information not only on global antibiotic pressure
but also on the number of patients exposed to
antibiotic pressure and the duration of pressure.
Whatever the indicators used, they should be
standardized to allow comparisons and bench-
marking.
Medico-economic aspects
Multiresistant bacteria, particularly MRSA and
ESBL-producing Enterobacteriaceae, are of concern
not only in hospitals where epidemics develop
but also in the community where the patients live
after hospital discharge and where antibiotic
pressure and cross-transmission occur, although
at lower levels than in the hospital setting.
To gain insights into multiresistant bacteria, and
to study the cost of antibiotic resistance, the
Massachusetts Division of Health Care Finance
and Policy collected data on patients with drug-
resistant infections discharged from Massachu-
setts Hospitals during the period 2000–2005. The
number of such patients steadily increased from
3861 to 9544 per year during this period. The main
changes over this period concerning the patients
discharged with resistant bacteria were a
decreased average length of stay, from 13.5 to
10.8 days and an increased proportion of patients
<65 years of age, from 32% to 42%. The main
organisms involved were MRSA (34%) and VRE
(10%). The main primary diagnoses of the patients
were pneumonia caused by S. aureus (6%), other
postoperative infections (4%), cellulitis and leg
abscesses (4%), UTIs (4%), pneumonitis due to
inhalation (3%) and S. aureus septicaemia (3%).
In 2005, the rate of patients discharged with
drug-resistant bacteria was 1.1% (range 0.6–2%,
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depending on the hospital), i.e. 9544 of the
836 811 discharges, 60% of them being older than
60 years. Approximately one-third of these cases
of resistance are thought to be due to antibiotic
use. These patients stayed 3.6 extra days in
hospital (9.1 vs. 5.5), incurring costs 46% higher
than those for patients without resistant bacteria
($24 173 vs. $16 553). The incremental cost of
resistance was at least $72 000 000 in 2005. The
main funding agencies for these patients were
Medicare (65%) and Medicaid (11%); that is, 76%
of the costs were covered by the government. The
current estimated annual cost of antibiotic resis-
tance in US hospitals is $30 000 000 000–
50 000 000 000 (assumptions being ﬁve to six
infections per 100 hospital admissions,
40 000 000 admissions per year, and excess costs
for resistance: an overall cost of $15 275 per
patient).
Non-traditional forces to change HAI
prevention
The CDC (SENIC project) and recent studies [15,
16] estimate that, globally, one third of all HAIs
and half of all SWIs, VAPs and CVC-related BSIs
could be prevented by strict implementation of all
CDC recommendations. However, 2 000 000
HAIs occur each year in the USA. Non-traditional
forces for change in HAI prevention are at work
in the USA, such as non-infection control, non-
proﬁt-organizations, individual states, patient
advocates and lawyers.
The Consumer Union, a non-proﬁt organiza-
tion ‘working for a fair, just and safe market place
for all ...’, launched a ﬁrst initiative, the ‘Stop
Hospital Infection Campaign’, requiring manda-
tory reporting of HAI rates in states through
legislation. As a result, in June 2007, 15 states
implemented such legislation, and reporting bills
are pending in virtually all other states. In
response, the Healthcare Infection Control Prac-
tices Advisory Committee issued recommenda-
tions for the organization of HAI Public
Reporting. Subsequently, the Consumer Union
launched a second initiative, ‘Mandatory imple-
mentation of MRSA control measures’. Seven
states have proposed legislation, based on SHEA
MRSA guidelines, and several other states are
developing such legislation. In response, a
SHEA ⁄Association for Professionals on Infection
Control and Epidemiology joint task force issued
a position statement concerning screening for
MRSA and VRE.
In 2004, the Institute for Healthcare Improve-
ment (http://www.ihi.org) launched the ‘100 000
lives campaign’ with the objective of saving
100 000 lives. Over 3100 hospitals representing
75% of US acute-care beds and discharges from
acute-care settings have, so far, enrolled in this
campaign, focusing on six targets, three of which
deal with HAIs (SWIs, ventilation and CVCs). As
an example, the CVC Bundle focuses on hand
hygiene, optimal insertion site, maximal sterile
barrier use, proper skin disinfection, daily review
of catheter necessity, early catheter removal and
intact dressings. In Johns Hopkins Hospital (Bal-
timore, USA), this initiative led to a CVC-related
BSI decrease from 11.3 to 0 per 1000 CVC-days,
thereby preventing 43 CVC-related BSIs and eight
deaths, and saving $1 945 922. Following the
same strategy, the Keystone Project launched by
the Michigan Hospital Association enrolled 127
ICUs, which led to the elimination of CVC-related
BSIs in 68 of these ICUs. Recently, the Institute for
Healthcare Improvement launched a ‘5 million
lives campaign’, expecting to enrol more than
4000 hospitals to prevent 5 000 000 incidents of
harm over the next 24 months (beginning in
2007). Among the speciﬁc targets, one concerns
HAIs, aiming to reduce MRSA infections by
reliably implementing scientiﬁcally proven infec-
tion control practices. MRSA prevention initia-
tives are underway in many places, e.g.Veterans
Administration hospitals, the Hospital Corpora-
tion of America, and the Volunteer Hospital of
America.
As a result of all these actions and reactions,
the strategy for HAI prevention is changing, and
non-proﬁt organizations, legislators and state
governments are making an increasing impact.
Non-traditional forces are more effective than
traditional ones, because they drive change
from the top (hospital director or administration)
rather than from the bottom. Medical malpractice
lawsuits are proliferating, and expenditures in
this context currently exceed what it would cost
to prevent all preventable HAIs.
CONCLUSION
Signiﬁcant changes have been occurring in the
ﬁeld of HAIs, which have now become a public
issue. Infections are better known and understood
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by the medical community. Countries have devel-
oped various policies to prevent HAIs, relying on
a wide array of tools and procedures. Among
these, the publication of HAI rates is important,
both to increase awareness on the part of deci-
sion-makers and to measure the efﬁcacy of rec-
ommendations, but such publications should
follow a strict scientiﬁc design. Hand hygiene is
the key to preventing all categories of HAI, and
the WHO campaign promoting AHRs should
have a worldwide impact. Speciﬁc policies, often
based on measures as simple and inexpensive as
hand washing, should be followed to prevent
CVC-related BSIs, SWIs and VAP.
In some countries, public activism has led to
new legislation, making compliance with HAI
preventive measures mandatory, whereas on the
other hand, lawsuits raise the cost of failing to
prevent HAIs.
Human motivation, as well as authority, is of
paramount importance in obtaining results in the
context of HAIs. This motivation should be collec-
tive, using all possible means of communication,
and should be based on local culture. The well-
known motto ‘think globally, act locally’ can be
fully applied to the control andprevention ofHAIs.
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